Laboratory of Biothermodynamics and Drug Design, Institute of Biotechnology, Graičiūno 8, Vilnius, Lithuania.
J Enzyme Inhib Med Chem. 2010 Dec;25(6):863-70. doi: 10.3109/14756360903571685. Epub 2010 Feb 18.
The binding and inhibition strength of a series of benzimidazo[1,2-c][1,2,3]thiadiazole-7-sulphonamides were determined for recombinant human carbonic anhydrase isoforms I, II, and IX. The inhibition strength was determined by a stop-flow method to measure carbon dioxide hydration. Inhibitor-enzyme binding was determined by two biophysical techniques--isothermal titration calorimetry and thermal shift assay. The co-crystal structure was determined by X-ray crystallography. Comparing the results obtained using three different inhibition and binding methods increased the accuracy of compound affinity ranking and the ability to determine compound inhibitory specificity towards a particular carbonic anhydrase isoform. In most cases, all three methods yielded the same results despite using very different approaches to measure the binding and inhibition reactions. Some of the compounds studied are submicromolar inhibitors of the isoform IX, a prominent cancer target.
一系列苯并咪唑[1,2-c][1,2,3]噻二唑-7-磺酰胺与重组人碳酸酐酶同工型 I、II 和 IX 的结合和抑制强度进行了测定。通过停流法测量二氧化碳水合作用来确定抑制强度。抑制剂-酶的结合通过两种生物物理技术——等温热滴定法和热转移测定法来确定。共晶结构通过 X 射线晶体学确定。使用三种不同的抑制和结合方法获得的结果进行比较,提高了化合物亲和力排序的准确性,并提高了确定化合物对特定碳酸酐酶同工型抑制特异性的能力。在大多数情况下,尽管使用非常不同的方法来测量结合和抑制反应,但三种方法都得到了相同的结果。研究的一些化合物是同工型 IX 的亚微摩尔抑制剂,IX 是一个重要的癌症靶点。